ACCELYA KALE SOLUTIONS
OPEN OFFER FOR ACQUISITION OF UP TO 3,782,966 FULLY PAID UP EQUITY SHARES OF THE FACE VALUE OF INR 10 EACH, REPRESENTING 25.34% OF THE VOTING SHARE CAPITAL OF ACCELYA SOLUTIONS INDIA LIMITED (“TARGET COMPANY”) FROM ALL THE PUBLIC SHAREHOLDERS OF THE TARGET COMPANY BY AURORA UK BIDCO LIMITED (“ACQUIRER”) TOGETHER WITH VISTA EQUITY PARTNERS PERENNIAL, L.P. (“PAC 1”) AND VISTA EQUITY PARTNERS PERENNIAL A, L.P. (“PAC 2”) (COLLECTIVELY “PACS”), AS THE PERSONS ACTING IN CONCERT WITH THE ACQUIRER (“OPEN OFFER” OR “OFFER”).AJMERA REALTY
With reference to above mentioned subject I, Shashikant Ajmera, as a Trustee of ARIIL TRUST, belonging to Promoter and promoter group of Ajmera Realty & Infra India Limited (hereinafter referred as Company), hereby intimate that ARIIL Trust has pledged 17,00,000 equity shares of Rs. 10/- each of the Company on 21st November, 2019.ALEMBIC PHARMA
Alembic Pharmaceuticals receives USFDA Approvals
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for its following Abbreviated New ['rug Applications (ANDAs):
1. Final Approval for Deferasirox Tablets 90 mg and 360 mg.
2. Final Approval for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg, and 500 mg.
3. Tentative Approval for Deferasirox Tablets 180 mg.
DHFL
Please note that the Company vide its letter no. DHFL/CSD/2019-20/1729 dated 20th November, 2019 had intimated that the Reserve Bank ofIndia ("RBI"), on 20th November, 2019, had superseded the board of directors ofthe Company and appointed Mr. R Subramaniakumar as the Administrator.
DR REDDY
"Dr. Reddy's Laboratories announces launch of Doxercalciferol Injection in the U.S. Market.Dr. Reddy's Laboratories Ltd. NYSE: ROY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Doxercalciferol Injection, 4 mcg/2 ml (2 mcg/ml) Multiple-Dose Vials, the therapeutic generic equivalent of Hectorol® (doxercalciferol) Injection 4 mcg/2 ml (2 mcg/ml) MultipleDose Vials, approved by the U.S. Food and Drug Administration (USFDA).
The Hectorol® Injection 4 mcg/2 ml (2 mcg/ml) Single-Dose Vials and Multiple-Dose Vials brand and generics had U.S. sales of approximately $138 million MAT for the most recent twelve months ending in September 2019 according to IQVIA Health
JYOTHY LABS
With reference to the Captioned subject and pursuant to your trading approval dated November --1-6-,2019, please note that company emplyee RAJNIKANTH SABNAVIS have sold 2,12,242 Equity Shares of the Company aggregating to 0.06% of the Paid-up Share Capital of the Company.LUPIN LTD
lupin launches "Adhero" first-of-its-kind connected Smart Device in India to support treatment of Respiratory Disease• First-of-its kind smart device launched in India to track usage pattern of metered dose inhaler (MDI) by patients
• Reusable device with built-in sensors to track daily usage and consumption pattern
• Companion app MyAdhero connects the device to smartphones via Bluetooth t hrough which patients can access information and set reminders
• Physicians using the app can monitor patient adherence to therapy to improve clinical outcomes
Mumbai, November 22, 2019: Pharma major Lupin Limited (Lupin) announced the launch of "ADHERO," a new connected smart device for metered-dose inhalers. This first-of-its-kind device is designed to help pat ients with ch ronic respiratory diseases track their MDI usage and facilitate improved adherence to therapy. Inhalers are the preferred treatment option for managing t he rising incidence of Chronic respiratory diseases like Asthma and COPD in India. However, it is estimated that nearly 45 percent patients do not adhere to therapy (in terms of filling I refil ling prescriptions or maintaining prescribed medication schedule), which adversely impacts clinical outcomes and patient quality of life. The new device, ADHERO, is designed to improve patient adherence to therapy.
Lupin has collaborated with Aptar Pharma, a leading provider of drug delivery devices, components and services in bringing this first in class device to market. ADHERO is a bluetooth-enabled, reusable smart device which attaches to the top of a MDI. With built-in sensors, the device tracks the patient's daily medication usage and consumption patterns. Patients can access this information by connecting their ADHERO device to the "MyAdhero" app on their smartphones. The app is also equipped to send reminders, provide contextual healt h alerts based on factors like Air Quality Index (AQI) at t he patient's current location and enable visual analytics. Physicians too can access patient-related information and medi cation tracking data through the patient dashboard portal as wel l as through the app. Speaking on the launch, Rajeev Sibal,
President India Region Formulations, Lupin Limited, said, "Lupin lays great emphasis on t hree aspects of Respiratory Medicine, namely Disease Awa reness, Diagnosis and Adherence. The launch of ADHERO will be a great help to patients using metered dose inhalers, as well as, for Doctors to track adherence and compliance to t herapy, t hereby improving cl inical outcomes and quality of life of patients." Lupin has always leveraged advanced technologies to support the treatment and awareness of medical conditions and this launch is a major stride in this direction.
Last year Lupin launched Anya, an artificial intelligence-powered health chatbot hosted on Face book Messenger to raise health awareness and help patients get medically verified responses to their disease and treatment-related queries. Originally configured to respond to diabetes and t uberculosis related queries, Any a now features enhanced capabilities of answering queries on Respiratory ailments like COPD and Ast hma, amongst others. Patients can simply search @askanyabot on Facebook Messenger to connect.